Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Current Liabilities: 2016-2024

Historic Total Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $40.7 million.

  • Rocket Pharmaceuticals' Total Current Liabilities fell 22.04% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.2 million, marking a year-over-year decrease of 22.04%. This contributed to the annual value of $40.7 million for FY2024, which is 16.12% down from last year.
  • Rocket Pharmaceuticals' Total Current Liabilities amounted to $40.7 million in FY2024, which was down 16.12% from $48.5 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Total Current Liabilities registered a high of $48.5 million during FY2023, and its lowest value of $22.2 million during FY2021.
  • For the 3-year period, Rocket Pharmaceuticals' Total Current Liabilities averaged around $42.8 million, with its median value being $40.7 million (2024).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Total Current Liabilities soared by 78.15% in 2020 and then crashed by 32.04% in 2021.
  • Over the past 5 years, Rocket Pharmaceuticals' Total Current Liabilities (Yearly) stood at $32.6 million in 2020, then tumbled by 32.04% to $22.2 million in 2021, then surged by 76.70% to $39.2 million in 2022, then climbed by 23.84% to $48.5 million in 2023, then dropped by 16.12% to $40.7 million in 2024.